• Valentyna Moyseyenko Bogomolets National Medical University, MD, Professor
  • Taras Medvedyev Bogomolets National Medical University
Keywords: chronic kidney disease, heart, calcium, phosphorus, metabolism


Introduction. It is known that patients with CKD are
more likely to die from cardiovascular causes than from
renal failure. These patients have almost 20 times higher
risk of cardiovascular events (CVD) [6]. In addition, even for
patients with CKD who do not require renal replacement
therapy, the rate of CVD is much higher than in patients
who reach end-stage renal disease and require renal
replacement therapy.
Goal. To study the parallels of mineral metabolism
disorders in patients with chronic kidney disease and
cardiovascular diseases.
Materials and methods. Review of modern and
foreign sources, analysis and discussion of a specific
clinical case; methods – description, analysis, abstracting.Results and discussion. Disorders of mineral
metabolism, in particular calcium-phosphorus homeostasis,
are presented and analyzed, are important complications
that occur in the early stages of chronic kidney disease
and progress with deteriorating renal function. A number
of studies in recent years have shown that higher or lower
than target levels of parathyroid hormone (PTH), Ca, P, Ca *
P product are closely correlated with increasing mortality of
nephrological patients [8, 9]. Thus, according to J. Floege
et al. (2011), in patients with stage V CKD and a PTH level
greater than 600 pg / ml, the risk of mortality is doubled
compared with patients in whom the PTH level is within the
target range [8]. In studies by Levin et al. it is shown that
the prevalence of secondary hyperparathyroidism (VGPT)
among patients with stage III – V CKD is 56% [10].
Conclusions. Patients on dialysis have disorders of
mineral metabolism, in particular calcium and phosphorus.
These disorders lead to excessive phosphate content.
Inhibition of these compensatory mechanisms requires
further study, as it plays an important role in the prevention
of cardiovascular complications in patients with chronic
kidney disease.


Національний реєстр хворих на хронічну хворобу нирок: 2010 рік/Уклад. Н.І. Козлюк, Г.С. Владзієвська, М.В. Кулизький; Державна установа «Інститут нефрології АМН України»; гол. ред. М.О. Колесник. – К., 2011. – 89. – 40 прим.

Meguid E.N. Chronic kidney disease: the global challenge / E.N. Meguid, A.K. Bello // Lancet. – 2005. – № 365. – Р. 331340.

United States Renal Data Systems. USRDS 2007 Annual Data Report: Atlas of EndStage Renal Disease

in the United States. Bethesda, MD: National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007.

Daly C. Is early chronic kidney disease an important risk factor for cardiovascular disease? A background paper prepared for the UK Consensus Conference on early chronic kidney disease // Nephrol. Dial. Transplant. – 2007. – № 22 (Suppl. 9). – Р. 1925.

United States Renal Data Systems. USRDS 2005 Annual Data Report: Atlas of EndStage Renal Disease in the United States. Bethesda, MD: National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2005.

Mendoza J.M., Isakova T., Cai X., Bayes L.Y., Faul C., Scialla J. Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease. // Kidney Int. – 2017. – V. 91. – I. 3. – P. 711–719.

Колесник М.О., Лапчинська І.І., Тащук В.К., Дядик О.І., Кулизький М.В. Кардіоваскулярні ускладнення у хворих на хронічну хворобу нирок. / Київ, 2010. – 224 с.

Floege J. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialisis population / J. Floege, J. Kim, E. Ireland, C. Chazot, T. Drueke // Nephrol. Dial. Transplant. – 2011. – № 26(6). – P. 19481955.

Anrann K. Hyperphosphataemia – a silent killer of paitients with renal failure // Nephrol. Dial. Transplant. – 1999. – Vol. 14(9). – P. 20852087.

Levin A. Prevalence of abnormal serum vitamin D, PTH, calcium and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease / Levin A., Bakris G.L., Molitch M. // Kidney Int. – 2007. – № 71. – P. 3138.

K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease // Am. J. Kidney Dis. – 2003. – Vol. 42(3). – P. 1201.

KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney DiseaseMineral and Bone Disorder (CKDMBD) // Kidney Int. — 2009. — 76 (suppl. 113). — S1130.

IDF Diabetes Atlas. 2015. – 7th Edition.

Llach F. Hyperphosphatemia in endstage renal disease patients: pathophysiological consequences // Kidney Int. – 1999. – Vol. 73. – P. 3137.

Malluche H.H. Understanding and managing hyperphosphatemia in patients with chronic renal disease / Malluche H.H., MonierFaugere M.C. // Clin. Nephrol. – 1999. – Vol. 52. – P. 267277.

Ganesh S.K. Association of elevated serum PO4, Ca*PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients / Ganesh S.K., Stack A.G., Levin N.W., HulbertShearon

T., Port F.K. // J. Am. Soc. Nephrol. – 2001. – Vol. 12. – P. 21312138.

Jüppner H., Wolf M., Salusky I. FGF23: More than a regulator of renal phosphate handling? / Jüppner H., Wolf M., Salusky I. // Journal of Bone and Mineral Research. – 2010. – Vol. 25. – Issue 10. – Р. 20912097.

Lim K., Lu T.S., Molostvov G., Lee C. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. // Circulation. – 2012. – V. 125. – P. 2243-2255.

Chang J.R., Guo J., Wang Y. et al. Intermedin1-53 attenuates vascular calcification in rats with chronic kidney disease by upregulation of α-Klotho. // Kidney Int. – 2016. – V. 89. – P. 586- 600.

Matkovic V, Heaney RP. Calcium balance during human growth: evidence for threshold behavior. Am.J.Clin.Nutr. 1992; 55:992–996. [PubMed: 1570810].

Friedman PA. Calcium transport in the kidney. Curr.Opin.Nephrol.Hypertens. 1999; 8:589–595. PubMed: 1054-1222.

Reilly RF. The patient with disorders of serum calcium and phosphate. In: Schrier RW (ed). Manual of nephrology. Sixth ed. Philadelphia: Lippincott Williams & Wilkins; 2005: 61-78.

Hoenderop JG, Nilius B, Bindels RJ. Calcium absorption across epithelia. Physiol Rev. 2005; 85:373–422. [PubMed: 15618484].

Imel EA, Econs MJ. Fibrous dysplasia, phosphate wasting and fibroblast growth factor 23. Pediatr. Endocrinol.Rev. 2007;

How to Cite
Moyseyenko , V., & Medvedyev , T. (2020). VIOLATION OF MINERAL EXCHANGE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND CARDIOVASCULAR DISEASES. Actual Problems of Nephrology, (26-27), 26-31.